Latest Articles

22. 11. 2021

Opinion of SÚKL's Department of Clinical Trials on Medicinal Products on Ongoing Clinical Trials and To-Be-Commenced Clinical Trials in Light of the COVID-19 Epidemiological Situation of 22 November 2021, added 25 November 2021

In view of the current serious and still worsening coronavirus epidemiological situation that can affect ongoing and newly initiated clinical trials, SÚKL hereby releases...

 

29. 10. 2021

List of reimbursed medicinal products valid as of 1.11.2021

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List...

 

30. 09. 2021

List of reimbursed medicinal products valid as of 1.10.2021

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List...

 

24. 09. 2021

Q&A for labelling

The requirements for labelling of Investigational medicinal products are given in European Commission guideline: The Rules Governing Medicinal Products in the European...

 

31. 08. 2021

List of reimbursed medicinal products valid as of 1.9.2021

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List...

 

27. 08. 2021

Pharmacovigilance activities within a specific therapeutic programme

State Institute for Drug Control (hereinafter “Institute”) publishes a list of pharmacovigilance activities for applicants for specific therapeutic programmes.

 

30. 06. 2021

List of reimbursed medicinal products valid as of 1.7.2021

Acting in compliance with Section 39n(1) of Act No. 48/1997 Coll., on Public Health Insurance, as amended (“Act”), the State Institute for Drug Control publishes the List...